OBJECTIVE: In many cases, the prognosis of an adrenocortical tumor cannot be determined from pathologic findings alone. We investigated cyclin E levels as a potential marker. METHODS: We studied 57 tumors by immunohistochemical staining with an anticyclin E antibody. We also evaluated clinical and pathologic factors (McFarlane staging and Weiss score) and previously validated genetic markers (17p13 loss of heterozygosity, 11p15 uniparental disomy, and overexpression of the IGF-II gene) for these tumors. Disease-free survival was estimated in 49 patients who underwent curative surgery. RESULTS: Cyclin E overproduction (> or =5%) was associated with the malignant phenotype and was strongly correlated with tumor size (P<0.0001), Weiss score (P<0.0001) and the presence of genetic abnormalities in tumors (P<0.001) (nonparametric Wilcoxon test and Fisher's exact test). Within a median follow-up of 44.1 months, seven patients exhibited a recurrence and two patients died from other causes. Cyclin E overproduction was significantly associated with shorter disease-free survival in univariate analysis (P=0.016; RR: 7.6), as were histologic grade (Weiss score > or =4; P=0.0006; RR: 18), 17p13 LOH (P=0.014, RR: 14.9), 11p15 UPD (P=0.003, RR: 11.8) and overexpression of the IGF-II gene (P=0.015, RR: 13.8). CONCLUSION: This study shows that cyclin E overproduction is of adverse prognostic significance in adrenocortical tumors.
OBJECTIVE: In many cases, the prognosis of an adrenocortical tumor cannot be determined from pathologic findings alone. We investigated cyclin E levels as a potential marker. METHODS: We studied 57 tumors by immunohistochemical staining with an anticyclin E antibody. We also evaluated clinical and pathologic factors (McFarlane staging and Weiss score) and previously validated genetic markers (17p13 loss of heterozygosity, 11p15 uniparental disomy, and overexpression of the IGF-II gene) for these tumors. Disease-free survival was estimated in 49 patients who underwent curative surgery. RESULTS: Cyclin E overproduction (> or =5%) was associated with the malignant phenotype and was strongly correlated with tumor size (P<0.0001), Weiss score (P<0.0001) and the presence of genetic abnormalities in tumors (P<0.001) (nonparametric Wilcoxon test and Fisher's exact test). Within a median follow-up of 44.1 months, seven patients exhibited a recurrence and two patients died from other causes. Cyclin E overproduction was significantly associated with shorter disease-free survival in univariate analysis (P=0.016; RR: 7.6), as were histologic grade (Weiss score > or =4; P=0.0006; RR: 18), 17p13 LOH (P=0.014, RR: 14.9), 11p15 UPD (P=0.003, RR: 11.8) and overexpression of the IGF-II gene (P=0.015, RR: 13.8). CONCLUSION: This study shows that cyclin E overproduction is of adverse prognostic significance in adrenocortical tumors.
Authors: Dai Horiuchi; Noelle E Huskey; Leonard Kusdra; Lara Wohlbold; Karl A Merrick; Chao Zhang; Katelyn J Creasman; Kevan M Shokat; Robert P Fisher; Andrei Goga Journal: Proc Natl Acad Sci U S A Date: 2012-04-03 Impact factor: 11.205
Authors: M Batisse-Lignier; I Sahut-Barnola; F Tissier; T Dumontet; M Mathieu; C Drelon; J-C Pointud; C Damon-Soubeyrand; G Marceau; J-L Kemeny; J Bertherat; I Tauveron; P Val; A Martinez; A-M Lefrançois-Martinez Journal: Oncogene Date: 2017-04-03 Impact factor: 9.867
Authors: Thomas J Giordano; Rork Kuick; Tobias Else; Paul G Gauger; Michelle Vinco; Juliane Bauersfeld; Donita Sanders; Dafydd G Thomas; Gerard Doherty; Gary Hammer Journal: Clin Cancer Res Date: 2009-01-15 Impact factor: 12.531
Authors: Alexandra Shaye; Aysegul Sahin; Qiang Hao; Kelly Hunt; Khandan Keyomarsi; Isabelle Bedrosian Journal: Breast Cancer Res Treat Date: 2008-12-24 Impact factor: 4.872
Authors: Sebastian R Aspinall; A H Imisairi; R D Bliss; D Scott-Coombes; B J Harrison; T Wj Lennard Journal: Ann R Coll Surg Engl Date: 2009-06-25 Impact factor: 1.891